These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 22314190)

  • 1. Gastric HER2 Testing Study (GaTHER): an evaluation of gastric/gastroesophageal junction cancer testing accuracy in Australia.
    Fox SB; Kumarasinghe MP; Armes JE; Bilous M; Cummings MC; Farshid G; Fitzpatrick N; Francis GD; McCloud PI; Raymond W; Morey A
    Am J Surg Pathol; 2012 Apr; 36(4):577-82. PubMed ID: 22314190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human epidermal growth factor receptor 2 testing in gastroesophageal cancer: correlation between immunohistochemistry and fluorescence in situ hybridization.
    Tafe LJ; Janjigian YY; Zaidinski M; Hedvat CV; Hameed MR; Tang LH; Hicks JB; Shah MA; Barbashina V
    Arch Pathol Lab Med; 2011 Nov; 135(11):1460-5. PubMed ID: 22032573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation assay enables accurate assessment of HER2 genomic status in gastric cancer and has potential utility in HER2 testing of biopsy samples.
    Yan B; Yau EX; Choo SN; Ong CW; Yong KJ; Pang B; Salto-Tellez M
    J Clin Pathol; 2011 Oct; 64(10):880-3. PubMed ID: 21757431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation and workflow optimization of human epidermal growth factor receptor 2 testing using INFORM HER2 dual-color in situ hybridization.
    Lim SJ; Cantillep A; Carpenter PM
    Hum Pathol; 2013 Nov; 44(11):2590-6. PubMed ID: 24075600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HER2 status in gastric/gastro-oesophageal junctional cancers: should determination of gene amplification by SISH use HER2 copy number or HER2: CEP17 ratio?
    Kumarasinghe MP; de Boer WB; Khor TS; Ooi EM; Jene N; Jayasinghe S; Fox SB
    Pathology; 2014 Apr; 46(3):184-7. PubMed ID: 24614718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chromogenic in situ hybridization (CISH) to detect HER2 gene amplification in breast and gastric cancer: comparison with immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH).
    Kiyose S; Igarashi H; Nagura K; Kamo T; Kawane K; Mori H; Ozawa T; Maeda M; Konno K; Hoshino H; Konno H; Ogura H; Shinmura K; Hattori N; Sugimura H
    Pathol Int; 2012 Nov; 62(11):728-34. PubMed ID: 23121603
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HER2 status in gastric and gastroesophageal junction cancer assessed by local and central laboratories: Chinese results of the HER-EAGLE study.
    Huang D; Lu N; Fan Q; Sheng W; Bu H; Jin X; Li G; Liu Y; Li X; Sun W; Zhang H; Li X; Zhou Z; Yan M; Wang X; Sha W; Ji J; Cheng X; Zhou Z; Xu J; Du X
    PLoS One; 2013; 8(11):e80290. PubMed ID: 24244671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bright-field in situ hybridization for HER2 gene amplification in breast cancer using tissue microarrays: correlation between chromogenic (CISH) and automated silver-enhanced (SISH) methods with patient outcome.
    Francis GD; Jones MA; Beadle GF; Stein SR
    Diagn Mol Pathol; 2009 Jun; 18(2):88-95. PubMed ID: 19430296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive analysis of HER2 expression and gene amplification in gastric cancers using immunohistochemistry and in situ hybridization: which scoring system should we use?
    Park YS; Hwang HS; Park HJ; Ryu MH; Chang HM; Yook JH; Kim BS; Jang SJ; Kang YK
    Hum Pathol; 2012 Mar; 43(3):413-22. PubMed ID: 21855114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simultaneous analysis of HER2 gene and protein on a single slide facilitates HER2 testing of breast and gastric carcinomas.
    Hirschmann A; Lamb TA; Marchal G; Padilla M; Diebold J
    Am J Clin Pathol; 2012 Dec; 138(6):837-44. PubMed ID: 23161718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HER2/neu gene amplification and protein overexpression in gastric and gastroesophageal junction adenocarcinoma: a review of histopathology, diagnostic testing, and clinical implications.
    Hechtman JF; Polydorides AD
    Arch Pathol Lab Med; 2012 Jun; 136(6):691-7. PubMed ID: 22646280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human epidermal growth factor receptor 2 testing in gastric carcinoma: issues related to heterogeneity in biopsies and resections.
    Lee S; de Boer WB; Fermoyle S; Platten M; Kumarasinghe MP
    Histopathology; 2011 Nov; 59(5):832-40. PubMed ID: 22092394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HER2 status in gastric cancer: a comparison of two novel in situ hybridization methods (IQ FISH and dual color SISH) and two immunohistochemistry methods (A0485 and HercepTest™).
    Pala EE; Bayol U; Ozguzer A; Akman O
    Pathol Res Pract; 2013 Sep; 209(9):548-54. PubMed ID: 23910175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HER2/neu testing in gastric cancer by immunohistochemistry: assessment of interlaboratory variation.
    Sheffield BS; Garratt J; Kalloger SE; Li-Chang HH; Torlakovic EE; Gilks CB; Schaeffer DF
    Arch Pathol Lab Med; 2014 Nov; 138(11):1495-502. PubMed ID: 25357111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathologic diagnostics of HER2 positivity in gastroesophageal adenocarcinoma.
    Koopman T; Louwen M; Hage M; Smits MM; Imholz AL
    Am J Clin Pathol; 2015 Feb; 143(2):257-64. PubMed ID: 25596252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HER2 in situ hybridization in gastric and gastroesophageal adenocarcinoma: comparison of automated dual ISH to FISH.
    Grin A; Brezden-Masley C; Bauer S; Streutker CJ
    Appl Immunohistochem Mol Morphol; 2013 Dec; 21(6):561-6. PubMed ID: 23455182
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [HER2 and gastric cancer. Recommendations for clinical practice in 2011].
    Penault-Llorca F; Chenard MP; Bouché O; Emile JF; Bibeau F; Metges JP; André T; Monges G
    Ann Pathol; 2011 Apr; 31(2):78-87. PubMed ID: 21601111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of immunohistochemistry, four in situ hybridization methods and quantitative polymerase chain reaction for the molecular diagnosis of HER2 status in gastric cancer: a study of 55 cases.
    Staněk L; Rozkoš T; Laco J; Ryška A; Petruželka L; Důra M; Dundr P
    Mol Med Rep; 2014 Nov; 10(5):2669-74. PubMed ID: 25189406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative analysis of diagnostic guidelines for HER2-status assessment.
    Stenzinger A; von Winterfeld M; Aulmann S; Warth A; Weichert W; Denkert C; Rüschoff J; Dietel M; Klauschen F
    J Mol Diagn; 2012; 14(3):199-205. PubMed ID: 22500949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Limited human epidermal growth factor receptor 2 discordance in metastatic breast cancer patients treated with trastuzumab, a population based study.
    van Rooijen JM; de Munck L; de Graaf JC; Siesling S; de Vries EG; Boers JE
    Eur J Cancer; 2014 Mar; 50(5):885-91. PubMed ID: 24491395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.